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Abstract 
The capacity of the angiotensin II (AngII) agonist [Sarl]AngII, the antagonist [Sari-Ile8]AngII and the non-peptidic antagonist DuP753 to undergo 
receptor internalization were studied in Chinese hamster ovary cells expressing rat AngII type la or 1 b receptors (AT,, or ATlb) or a mutant of AT,, 
(Asn”) unable to couple G-protein. In this expression system, the ligand-induced internalization of rat AT,, and AT,, are similar. Moreover, peptidic 
ligands, either the agonist or antagonist, induce a significant internalization of AT, receptors, but the non-peptidic antagonist DuP753 is far less 
potent. Finally, the normal internalization of the mutant Asn74 demonstrates that receptor activation and G-protein coupling are not required for 
AT,, internalization. 
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1. Introduction 
Two pharmacologically distinct classes of receptors 
have been identified for the vasoactive peptide angioten- 
sin II (AngII): AT, and AT2 [1,2]. Both of them belong 
to the seven transmembrane domain receptor family [3- 
6]. The precise functions and intracellular signalling 
pathways of AT, have not yet been well defined. AT, 
receptors are responsible for most of the classical physi- 
ological actions of AngII by interacting with a G-pro- 
tein, which induces phospholipase C (PLC) activation 
and the subsequent cascade of intracellular events 
(phosphoinositide hydrolysis, calcium signalling, protein 
kinase C activation) [7]. Two AT, isoforms (AT,, and 
AT,,) that are encoded by different genes have been 
identified in rodents [&lo]. AT,, and AT,,, have different 
patterns of expression, in terms of tissue specificity 
[ 11,121 and expression during development (J.-M. Gasc, 
personnal communication), but no major difference in 
their pharmacology and signalling pathways has been 
identified up to now [11,13]. 
demonstrated for other membrane-bound receptors, 
such as those for transferrin or EGF [ 17,181. Internaliza- 
tion of the AngII-AT, complexes has been described in 
adrenal glomerulosa cells [19,20] and vascular smooth 
muscle cells [21,22] using radioiodinated ligands. How- 
ever, the nature of the AT, subtype involved in this proc- 
ess and the molecular mechanisms underlying this proc- 
ess, such as receptor activation and G-protein coupling, 
are not known. Mutational analysis of different G-pro- 
tein coupled receptors has shown that coupling to a G- 
protein may or not be a prerequisite for internalization, 
depending on the nature of the receptor and its cognate 
G-protein [23,24]. 
Several questions are addressed in the present study: 
(i) is there any difference in internalization of AT,, and 
AT,,, receptors?; (ii) are the peptidic or non-peptidic an- 
alogs of AngII similarly internalized?; and (iii) is a func- 
tional G, coupled AT, receptor required for internaliza- 
tion? 
Agonist-induced receptor internalization occurs dur- 
ing activation of a large number of cell surface receptors, 
including G-protein coupled receptors [14]. There is in- 
creasing evidence that the binding of the ligand to G- 
protein coupled receptors induces a lateral movement of 
ligand-receptor complexes followed by their association 
with coated pit structures and their subsequent internal- 
ization [15,16]. This process has already been clearly 
For this purpose, three different recombinant forms of 
AT, were separately expressed in CHO cells and ana- 
lyzed for their capacity to internalize the AngII peptidic 
agonist [Sarl]AngII, the peptidic antagonist [Sarl- 
IleS]AngII and the non-peptidic antagonist DuP753 (or 
losartan). The three recombinant receptors used were 
wild-type rat AT,, and AT,, and a rat AT,,, shown to 
be incapable of coupling to the G-protein [25], in which 
a conserved charged residue of the second transmem- 
brane domain had been mutated (Asp74+Asn). 
*Corresponding author. Fax: (33) (1) 44 27 16 91. 2. Materials and methods 
Abbreviations: AngII, angiotensin II; [Sarl]AngII, [sarcosine-I] angio- 
tensin II; [Sari-Ile8]AngII, [sarcosine-l jsoleucine-8langiotensin II; 
PLC, phospholipase C; PKC, protein kinase C; IP, inositol phosphate; 
CHO, Chinese hamster ovary. 
2.1. Transfection and expression 
CHO AT,, and CHO Asn74 clones were described previously [25,26]. 
In order to establish CHO AT,, clones, the plasmid PEAT,~ was con- 
structed by inserting the AT,, cDNA insert of the plasmid pCDNAI- 
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IAT,, (a generous gift from K. Sandberg) into the Not1 and EcoRl sites 
of the expression vector pECE [27]. Cells were co-transfected with IO 
pg PEAT,, and 2 fig of the selection marker pSV2neo by the calcium 
phosphate precipitation method [28]. Transfected cells were selected by 
their resistance to 75Opg/ml G418 (Gibco). Individual resistant colonies 
expressing high levels of AT,, were cloned by limiting dilution. 
2.2. Cell culture 
CHO Kl-transfected cells were maintained in Ham’s F12 medium 
supplemented with 10% fetal calf serum plus 0.5 mM glutamine, 100 
U/ml penicillin and 100 &ml streptomycin (all from Boehringer- 
Mannheim). 
2.3. Functional characterization 
[Sarcosine- l]AngII and [Sarcosine- I, Isoleucine-8]AngII 
([SarIlAng and [Sarl-IleS]AngII, Sigma) were labelled by the chlo- 
ramine T method [29] and monoiodinated products were purified by 
HPLC. 
For saturation binding assays, cells were subcultured into 24-well 
culture trays and incubated for45 min at 22°C with various ‘251-labelled 
[SarIlAng concentrations in 50 mM Tris-HCI, 6.5 mM MgCI,, 125 
mM NaCI, 1 mM EDTA and 1 mglml BSA, pH 7.6. For competitive 
binding assays, cells were incubated in the same buffer with 0.5 nM 
[‘ZSI][Sarl]AngII and various concentrations of competing ligands. 
Non-specific binding was determined in the presence of I PM AngII. 
Each experiment was carried out in duplicate. Binding data were analy- 
sed with a non-linear least-squares curve fitting procedure, Ebda-Li- 
gand (Elsevier-Biosoft, Cambridge, UK) [30]. 
[‘Hllnositol phosphate (IP) production in response to increasing con- 
centrations of AngIl or [Sarl-IleB]AngII was determined in CHO AT,, 
and CHO AT,, ceils, essentially as previously described [31]. Cells were 
labelled with 2 uCi/ml I’Hlmvoinositol for 24 h and then incubated with 
AnglI or [Sari-Ile8]AngII for 30 min in the presence of 10 mM LiCI. 
After purification on a Dowex 1 x 8 anion exchange resin (Bio-Rad), 
the total IP fraction was measured. 
2.4. Internalization assay 
Two procedures were used depending on the ligand. For radioactive 
agonist or antagonist peptides, cells in 24-well culture trays were placed 
at 4°C washed with PBS and incubated for 180 min in binding buffer 
containing [‘*SI][Sarl]AngII or [‘251][Sarl-Ile8]AngII, in the absence 
(total binding) or presence (non-specific binding) of I PM AngII. The 
concentrations of radioligands used corresponded to the previously 
determined dissociation constant (&) so that approximately 50% of the 
receptor were occupied. Cells were then washed twice with 0.5 ml 
ice-cold binding buffer and incubated at 37°C for various times to 
permit internalization. Finally, the cells were placed at 4°C and washed 
once in binding buffer. Half of the replicate wells were immediately 
incubated with 0.5 ml of 1 N NaOH and the solution counted to 
determine total and non-specific binding at each time. In the other 
wells, the radioactivity bound to the surface of the cells was eluted by 
a 5 min incubation in 0.5 ml of ice-cold buffer containing 50 mM glycine 
and 125 mM NaCl, pH 3. Cells were washed with an additional 0.5 ml 
of this buffer, and radioactivity in the combined acid washes was 
counted and considered to represent the total and non-specific surface- 
associated radioactivity. Radioactivity remaining within the cells after 
acid treatment was solubilized with 0.5 ml of I N NaOH and was 
considered to represent total and non-specific internalized radioactiv- 
ity. The sum of the specific surface-bound and internalized fractions 
was comparable to the total specific binding measured, thus verifying 
the validity of this procedure. When the radiolabelled ligand was 
[‘HIDuP (NEN), the procedure for measuring receptor internaliza- 
tion was modified because the binding steady state was only obtained 
after incubation at 4°C for 24 h. Since this resulted in significant cell 
loss, the binding and internalization were realized together at 37°C for 
varying times. After these incubations the cells were placed at 4”C, 
washed twice in ice-cold buffer and processed as above. To confirm that 
acid-resistant radioactivity corresponds to internalization of the li- 
gand-receptor complexes, cells were incubated in binding buffer with 
or without 0.4 M sucrose for 30 min at 37°C prior to a 15 min exposure 
to [‘HIDuP under the same conditions. For [‘**I][Sarl]AngII or 
[‘251][Sarl-Ile8]AngII the procedure was as described above except that 
0.4 M sucrose was present during the binding and internalization 
(20 min at 37°C) steps. Cells were then processed normally. 
3. Results 
The pharmacological and signalling properties of AT,, 
and AT,,, receptors expressed separately in CHO cells 
were first evaluated. As indicated in Table 1, CHO AT,, 
and CHO AT,, exhibit a similar unique high affinity 
binding site (& = 1.07 + 0.03 nM and 1.23 + 0.14 nM, 
respectively). The density of receptors in CHO AT,, 
(B,,, = 3.54 + 0.84 x 10’ sites/cell) is twofold higher 
than in CHO AT,, (B,,__ = 1.65 + 0.39 x lo5 sites/cell), 
reflecting clonal variations. Competition assays with 
[Sarl-Ile8lAngII and DuP753 show no significant differ- 
ence in the Ki of these two antagonists for AT,, and AT,, 
receptors. 
The production of IP in response to increasing concen- 
trations of AngII was then compared in CHO AT,, and 
CHO AT,, (Fig. 1). The half maximal response was 
obtained with similar doses of AngII in CHO AT,, (EC,,, 
= 0.49 ? 0.07 nM) and CHO AT,, (EC,, = 0.37 + 0.04 
nM) (non significant difference). However, the maximal 
response obtained for CHO AT,,, was 60% higher than 
that of CHO AT,,. Analysis of the maximal IP response 
in several clones of CHO AT,, expressing this recombi- 
nant receptor at different densities (data not shown) 
clearly indicates that the maximal IP response correlates 
with the B,,,,,. Therefore the most likely explanation for 
the increased maximal IP response in the CHO AT,,, cell 
line is the higher level of expression of AT,I, receptors. 
The production of IP in response to increasing concen- 
trations of [Sarl-Ile8lAngII was assayed in CHO AT,, 
and CHO AT,, cells. The partial agonist activity of this 
compound observed in some cellular models [32] could 
not be detected in these cells since the intracellular IP 
level remained similar to the basal level with up to 10e6 
M [Sar 1-Ile8lAngII. 
Ligand-mediated internalization of the AT,, and AT,b 
was analysed for three different ligands. Fig. 2a shows 
the time-course of internalization for these two receptors 
when it was induced by [Sarl]AngII, a peptidic agonist 
of AngII. Maximal internalization was obtained after 
Table I 
Pharmacological characterization of rat AT,, and AT,, receptors ex- 
pressed in CHO cells 
AT,, AT,b n 
(4 Kd (nW 1.07 f 0.03 1.23 + 0.14 3 
B,,, ( lo5 sites/cell) I .65 f 0.39 3.54 + 0.84 3 
0) K, WV 
[Sari-IleS]AngII 
DuP753 
0.83 f 0.18 0.67 + 0.23 3 
2.81 f 0.25 2.53 + 0.46 3 
(a) Binding parameters of [‘ZSI][Sarl]AngIl 
(b) Affinities of both receptor subtypes for a peptidic and a non-peptide 
antagonist. 
Data represent the mean + S.E.M. obtained from the indicated number 
of experiments (n) with each point being performed in duplicate 
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Fig. 1. AngIl-induced stimulation of inositol phosphate production. 
Total inositol phosphates were measured in CHO AT,, (A) and CHO 
AT,, (0) cloned cell lines, in the presence or absence of increasing 
amounts of AngII. Results are expressed as the ratio of the cpm in 
stimulated vs. unstimulated cells and represent the mean f S.E.M. of 
three independent experiments performed in triplicate. 
20 min at 37°C and was 84.28 * 1.54% and 
78.68 ? 1.38% of the total specific binding for AT,, and 
AT,,, respectively. The time necessary to internalize 50% 
of the ligand-receptor complex (t,,,) was 5 min for both 
receptors. Receptor internalization mediated by a pep- 
tidic antagonist ([Sarl-Ile8lAngII) was then analyzed 
(Fig. 2b). Internalized radioactivity increased to a maxi- 
mum (77.26 + 3.86% for AT,, and 75.60 f 3.25% for 
AT,,,) after 20 min at 37°C. In the presence of sucrose, 
only 5% of this radioactivity was detected, indicating 
that 95% of the acid-resistant radioactivity corresponded 
to internalization via clathrin-coated pits (data not 
shown). The t,,, was also of approximately 5 min for the 
two isoforms. Finally, the internalization induced by a 
non-peptidic antagonist (DuP753) is shown in Fig. 3a. 
The acid-resistant [3H]DuP753 fraction reached a maxi- 
mum of 29.58 + 3.34% after 10 min at 37°C for AT,, and 
28.09 ? 2.09% after 15 min at 37°C for AT,,. To verify 
that the acid-resistant fractions did not represent incom- 
plete dissociation of the bound DuP753 during the acid 
wash procedure rather than a specific internalization 
process, the effect of sucrose, which is known to abolish 
receptor internalization via clathrin-coated pits was 
studied [33]. As shown in Fig. 3b, approximately 60% of 
the acid-resistant radioactivity associated with either 
AT,, or AT,,, is inhibited by sucrose. Therefore, approx- 
imately 17% of the bound [3H]DuP753 is internalized. 
To determine whether G-protein coupling is required 
for AT, internalization, we have analysed the internali- 
zation of an AT,, receptor which contains a point muta- 
tion (Asp74+Asn) that has been shown to abolish G- 
protein coupling of the receptor. As can be seen in Fig. 
2a and b, the uncoupled AT,, receptor is internalized to 
the same extent as the wild-type, after binding of 
[‘251][Sarl]AngII or [1251][Sarl-Ile8]AngII at 4°C. 
[3H]DuP753-mediated internalization of this mutant 
could not be assayed because of the low affinity of the 
mutated receptor for this compound (Ki = 17 nM). 
4. Discussion 
AT, receptors belong to the large family of seven 
transmembrane domain receptors of which the more fa- 
miliar examples include the adrenergic, dopaminergic, 
serotoninergic, muscarinic and pituitary hormone recep- 
tors [34]. Several of these classes of receptors are com- 
posed of multiple isoforms, all of which bind a specific 
agonist but differ by their pharmacology and/or by their 
signal transduction mechanisms. In the case of AT, re- 
ceptors, two subtypes have been clearly identified in ro- 
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Fig. 2. [Sarl]AngII- and [Sari-Ile8]AngII-induced receptor internaliza- 
tion. CHO cells expressing AT,, (A), AT,,, (0) or Asn74 (0) were prela- 
belled with [‘251][Sarl]AngII (a) or [‘251][Sarl-Ile8]AngII (b) on ice for 
approximately 3 h. The cells were then washed and incubated at 37°C 
for various time periods, to allow internalization. Non-internalized 
tracer was removed by acid washing, and internalized tracer levels were 
determined after NaOH treatment. Results are expressed as percent of 
total specific binding and represent the mean f S.E.M. of three inde- 
pendent experiments performed in duplicate. 
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functional differences are still a matter of debate. It was 
therefore important to first compare the pharmacologi- 
cal properties and signalling mechanisms of AT,, and 
AT,,,, before investigating potential internalization dif- 
ferences. 
The most extensive comparison of rat AT,, and AT,, 
pharmacologies was recently described by Chiu et al. [ 131 
in CHO cells and did not show any significant differences 
in the pharmacological profiles of the two receptors. 
However, Sandberg et al. [9] have reported that AT,, 
transiently expressed in COS cells has a slightly higher 
affinity for [desAspl]AngII as compared to that of AT,, 
reported in the literature. The preliminary results pre- 
sented here indicate no major difference in the pharma- 
cological profiles of these two receptors, confirming the 
results of Chiu et al. 
a 
100, 




Fig. 3. DuP753-induced receptor internalization. a: CHO cells express- 
ing AT,, (A) or AT,, (0) were incubated with [ZH]DuP753 for various 
time periods at 37°C. b: Cells were preincubated for 30 minutes at 37°C 
with (hatched bars) or without (open bars) 0.4 M sucrose, prior to a 
15 minute incubation with [‘HIDuP in the same buffer at 37°C. In 
both cases, cells were then placed on ice and after extensive acid wash- 
ing, the remaining cell-associated radiactivity was determined after 
NaOH treatment. Results are expressed as percent of total specific 
binding and represent the mean + SEM of three independent experi- 
ments performed in duplicate. 
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Both AT,, and AT,, activate PLC, which results in an 
increase in intracellular inositol-( 1,4,5)-trisphosphate 
and diacylglycerol concentrations leading to intracellular 
calcium mobilization and PKC activation. No major dif- 
ference in the signalling pathways of rat AT,, and AT,, 
has been reported so far [1 11. However, a difference has 
been reported in the shape of the dose-response curve for 
Ca*+ mobilization at high concentrations of AngII 
(>lO-’ M), when rat AT,, or AT,, mRNAs were 
injected into Xenopus oocytes. The maximal response 
mediated by the rat AT,, was lower at the higher ligand 
concentrations, whereas the maximal response was 
maintained for the rat AT,, [9]. In the present study, 
where the AT, receptors were expressed in CHO cells, 
these differences were not observed for another second 
messenger (IP), therefore suggesting a cell- or species- 
specific phenomenon. 
In conclusion, the preliminary comparative character- 
ization of AT,, and AT,,, receptors did not identify func- 
tional differences and the study was therefore extended 
to the internalization process. 
Internalization of natural AngII receptors was previ- 
ously studied in two main cellular models: rat vascular 
smooth muscle cells which express mainly the AT,, sub- 
type, and bovine adrenocortical cells which express a 
single AT, receptor species. When AngII agonist ligands 
were used, as much as 80% of the bound analog was 
internalized and the t,,, ranged from 1.5 to 10 min in 
these cells [ 19-221. Interestingly, differences were ob- 
served in the internalization of AngII peptidic antagonist 
as rat vascular smooth muscle cells were found to inter- 
nalize AngII peptidic agonists and antagonists to the 
same extent [35], whereas bovine adrenocortical cells 
only internalize lo-25% of the peptidic antagonist [19]. 
The present data show that the peptidic agonist 
[Sarl]AngII and antagonist [Sarl-IleS]AngII are inter- 
nalized to the same extent (80%) by both AT,, and AT,, 
and have similar kinetics of internalization (t,,, = Smin 
and t,,, = 20 min). As similar profile of internalization 
are observed for the peptidic antagonist with both rat 
AT,, and AT,,, it is apparent that the species-specific 
differences in response to AngII peptidic antagonist are 
not displayed by the two rat AT, isoforms. 
Another interesting observation is the low level (17%) 
of receptor internalization induced by the non-peptidic 
AngII antagonist DuP753, via clathrin coated pits. A low 
rate of internalization, via this pathway, has also been 
reported for the insulin receptor, using specific antibod- 
ies as ligand. This observation led to the identification 
of the constitutive pathway of internalization as opposed 
to the ligand-induced pathway [36]. There is no clear 
demonstration of constitutive internalization of G-pro- 
tein coupled receptors, but it can be postulated that 
DuP753 internalizes via a constitutive and not a ligand- 
dependent pathway. Such an hypothesis merits further 
study. 
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Finally, a previously described mutant of the rat AT,, 
receptor was used to analyse the relationship between 
G-protein coupling and receptor internalization. This 
mutant was selected because the single mutation of 
Asp74-to-Asn does not alter the affinity of the receptor 
for peptidic agonists, but results in a receptor unable to 
transduce any measurable signal into CHO cells after 
agonist binding [25]. This receptor was found to internal- 
ize normally with either peptidic agonist or antagonist, 
thus excluding a role for G-protein coupling and/or ef- 
fector activation in internalization of the AT,, receptor 
subtype. This conclusion is also sustained by the normal 
internalization of peptidic antagonists, which do not ac- 
tivate the signalling pathway. 
This result seems to be unique among the G-protein 
coupled receptors which activate PLC. Accumulated 
data indicate that, in this subfamily, G-protein coupling 
is needed for internalization. For example the mutation 
of Asp” in the second transmembrane domain of the 
TRH receptor results in an inactive receptor which inter- 
nalizes very poorly (15% vs. 60% for the wild-type) [23]. 
The homologous mutation of the Ml muscarinic recep- 
tor expressed in U293 human kidney cells produces a 
similar result [37]. Moreover compounds such as the 
aminosteroid U73122, which directly inactivate the G- 
protein that couples to the M3 muscarinic receptor, in- 
hibit the internalization of this receptor [38]. 
In the subfamily of receptors coupled to G,-protein 
and adenylate cyclase, there is no apparent link between 
G-protein coupling and internalization. Several muta- 
tions of the third intracellular loop and proximal car- 
boxyl-terminal domain of the /?,-adrenergic receptor im- 
pair G-protein coupling but not internalization [24]. 
Moreover, while another deletion of the amino-terminal 
part of the third intracellular loop of the hamster 
P,-adrenergic receptor resulted in the destruction of its 
ability to both couple to G,-protein and undergo ligand- 
mediated internalization, replacement of the deleted re- 
gion by the corresponding region of the Ml muscarinic 
receptor restored internalization but not G-protein cou- 
pling [39,40]. 
The nature of the mutations introduced in each of 
these receptors may explain the variable implication of 
G-protein coupling in internalization. However, it is un- 
likely since the same mutation in the second transmem- 
brane domain of either AT, or TRH and Ml muscarinic 
receptors results in similar G-protein uncoupling but dif- 
ferent internalization profiles. Our results suggest hat, 
while normal G-protein coupling is required for internal- 
ization of some of these receptors, a conformational 
change of the specific structural motif that mediates in- 
ternalization can occur independently of G-protein cou- 
pling for other receptors (such as AT,). Thus, this inter- 
nalization process depends more on the nature of the 
receptor than on the nature of its signalling pathway. We 
can postulate that AT, receptor internalization, like that 
of the j?-adrenergic receptors, has conformational rather 
than functional requirements. 
In conclusion, the present study provides the first evi- 
dence that both AT,, and AT,, are able to undergo 
internalization upon interaction with either AngII pep- 
tidic agonist or antagonist, but that non-peptidic antago- 
nists are poorly internalized. Furthermore, it demon- 
strates that AT, receptors are unique among the G-pro- 
tein coupled receptors which activate PLC as there is no 
link between activation of the signalling pathway and 
receptor-ligand internalization. 
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